Eric Clambey
Concepts (410)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gammaherpesvirinae | 8 | 2021 | 45 | 1.990 |
Why?
| | Herpesviridae Infections | 6 | 2021 | 148 | 1.460 |
Why?
| | CD8-Positive T-Lymphocytes | 13 | 2021 | 918 | 1.350 |
Why?
| | Gene Expression Regulation, Viral | 5 | 2021 | 99 | 1.200 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 2021 | 393 | 1.100 |
Why?
| | B7-H1 Antigen | 5 | 2024 | 221 | 0.880 |
Why?
| | Receptor, Adenosine A2B | 4 | 2013 | 59 | 0.790 |
Why?
| | Immunologic Memory | 8 | 2020 | 360 | 0.750 |
Why?
| | Head and Neck Neoplasms | 7 | 2022 | 553 | 0.730 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2020 | 369 | 0.710 |
Why?
| | Virus Replication | 4 | 2021 | 532 | 0.700 |
Why?
| | RNA, Untranslated | 3 | 2021 | 124 | 0.690 |
Why?
| | Mice | 44 | 2024 | 18048 | 0.680 |
Why?
| | Virus Latency | 6 | 2021 | 80 | 0.680 |
Why?
| | Host-Pathogen Interactions | 3 | 2019 | 372 | 0.660 |
Why?
| | Flow Cytometry | 5 | 2018 | 1197 | 0.650 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2560 | 0.630 |
Why?
| | Virus Activation | 5 | 2021 | 86 | 0.620 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2024 | 1431 | 0.610 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 175 | 0.610 |
Why?
| | Animals | 56 | 2024 | 37657 | 0.600 |
Why?
| | Immunomodulation | 2 | 2019 | 101 | 0.600 |
Why?
| | Ischemia | 4 | 2015 | 415 | 0.590 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2020 | 316 | 0.580 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 660 | 0.540 |
Why?
| | Clone Cells | 3 | 2008 | 266 | 0.540 |
Why?
| | Tumor Microenvironment | 9 | 2021 | 692 | 0.520 |
Why?
| | Interleukin-10 | 1 | 2019 | 310 | 0.520 |
Why?
| | Mice, Inbred C57BL | 24 | 2023 | 5887 | 0.510 |
Why?
| | Ikaros Transcription Factor | 2 | 2013 | 24 | 0.490 |
Why?
| | G(M1) Ganglioside | 1 | 2015 | 7 | 0.480 |
Why?
| | Kidney Diseases | 2 | 2020 | 406 | 0.480 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2021 | 80 | 0.470 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 335 | 0.460 |
Why?
| | Hypoxia | 2 | 2013 | 1164 | 0.460 |
Why?
| | RNA, Viral | 1 | 2019 | 693 | 0.460 |
Why?
| | T-Lymphocytes | 4 | 2017 | 2002 | 0.460 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2024 | 830 | 0.450 |
Why?
| | Diagnostic Imaging | 1 | 2018 | 326 | 0.450 |
Why?
| | Mice, Transgenic | 10 | 2019 | 2180 | 0.430 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2021 | 192 | 0.430 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 469 | 0.430 |
Why?
| | Mice, Knockout | 11 | 2023 | 3068 | 0.420 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 3 | 2023 | 266 | 0.410 |
Why?
| | Antibodies | 1 | 2015 | 409 | 0.400 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 772 | 0.400 |
Why?
| | Forkhead Transcription Factors | 2 | 2019 | 199 | 0.390 |
Why?
| | RNA, Messenger | 2 | 2019 | 2828 | 0.390 |
Why?
| | Aging | 5 | 2018 | 1892 | 0.380 |
Why?
| | Interleukin-12 | 1 | 2013 | 123 | 0.380 |
Why?
| | Cisplatin | 2 | 2024 | 327 | 0.380 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2020 | 1250 | 0.380 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2020 | 1110 | 0.360 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2012 | 286 | 0.350 |
Why?
| | Gene Expression Regulation | 4 | 2015 | 2599 | 0.350 |
Why?
| | Immunotherapy | 4 | 2021 | 640 | 0.350 |
Why?
| | Kidney | 5 | 2023 | 1482 | 0.350 |
Why?
| | Endotoxins | 1 | 2012 | 220 | 0.340 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 245 | 0.340 |
Why?
| | Radioimmunotherapy | 2 | 2021 | 21 | 0.340 |
Why?
| | Neutrophils | 2 | 2017 | 1282 | 0.340 |
Why?
| | Radiation Tolerance | 3 | 2021 | 104 | 0.340 |
Why?
| | Pneumonia | 3 | 2017 | 656 | 0.320 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2020 | 257 | 0.310 |
Why?
| | Cyclins | 2 | 2021 | 92 | 0.290 |
Why?
| | Mice, Inbred BALB C | 8 | 2021 | 1274 | 0.290 |
Why?
| | STAT3 Transcription Factor | 2 | 2020 | 204 | 0.290 |
Why?
| | Open Reading Frames | 2 | 2018 | 132 | 0.280 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1123 | 0.280 |
Why?
| | Interferon-gamma | 3 | 2020 | 792 | 0.270 |
Why?
| | Acute Kidney Injury | 2 | 2012 | 819 | 0.270 |
Why?
| | Signal Transduction | 6 | 2019 | 5144 | 0.270 |
Why?
| | Oxygen | 1 | 2013 | 993 | 0.270 |
Why?
| | Immunophenotyping | 2 | 2019 | 329 | 0.260 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 631 | 0.260 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2018 | 15 | 0.260 |
Why?
| | Viral Proteins | 4 | 2021 | 369 | 0.250 |
Why?
| | Inflammation | 4 | 2020 | 2890 | 0.250 |
Why?
| | Nuclear Proteins | 2 | 2021 | 712 | 0.240 |
Why?
| | Papillomavirus Infections | 2 | 2022 | 380 | 0.220 |
Why?
| | Dendritic Cells | 2 | 2021 | 505 | 0.220 |
Why?
| | Cell Line, Tumor | 9 | 2024 | 3469 | 0.210 |
Why?
| | Antigens, Viral | 2 | 2021 | 179 | 0.200 |
Why?
| | Disease Models, Animal | 7 | 2020 | 4404 | 0.200 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2166 | 0.200 |
Why?
| | Cell Proliferation | 6 | 2020 | 2504 | 0.200 |
Why?
| | Immunity, Cellular | 2 | 2019 | 269 | 0.200 |
Why?
| | Spleen | 2 | 2002 | 525 | 0.200 |
Why?
| | Humans | 35 | 2024 | 141187 | 0.200 |
Why?
| | Lymphocyte Depletion | 2 | 2021 | 135 | 0.200 |
Why?
| | Cell Separation | 2 | 2018 | 317 | 0.190 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2020 | 72 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 98 | 0.190 |
Why?
| | Peritoneal Cavity | 1 | 2002 | 31 | 0.190 |
Why?
| | Polycystic Kidney Diseases | 1 | 2023 | 73 | 0.190 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 118 | 0.190 |
Why?
| | Acute Lung Injury | 2 | 2017 | 304 | 0.180 |
Why?
| | Sequence Deletion | 1 | 2002 | 183 | 0.180 |
Why?
| | Lymphocytic choriomeningitis virus | 2 | 2018 | 33 | 0.180 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 959 | 0.180 |
Why?
| | Adaptive Immunity | 2 | 2023 | 173 | 0.180 |
Why?
| | Tryptophan | 1 | 2023 | 188 | 0.180 |
Why?
| | RNA Polymerase III | 1 | 2021 | 28 | 0.180 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2024 | 256 | 0.170 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1049 | 0.170 |
Why?
| | Immune Tolerance | 2 | 2020 | 368 | 0.170 |
Why?
| | Gamma Rays | 1 | 2020 | 57 | 0.170 |
Why?
| | Epithelial Cells | 3 | 2018 | 1110 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 112 | 0.160 |
Why?
| | Aldehyde-Lyases | 1 | 2020 | 3 | 0.160 |
Why?
| | Cells, Cultured | 5 | 2018 | 4208 | 0.160 |
Why?
| | Thymocytes | 1 | 2020 | 35 | 0.160 |
Why?
| | Splenectomy | 1 | 2020 | 62 | 0.160 |
Why?
| | Sphingosine | 1 | 2020 | 45 | 0.160 |
Why?
| | Ileitis | 1 | 2020 | 32 | 0.160 |
Why?
| | Complement Factor H | 1 | 2020 | 79 | 0.150 |
Why?
| | Lysophospholipids | 1 | 2020 | 80 | 0.150 |
Why?
| | Discoidin Domain Receptor 2 | 1 | 2019 | 6 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.150 |
Why?
| | Ephrin-B2 | 1 | 2019 | 45 | 0.150 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1242 | 0.150 |
Why?
| | Cell Line | 7 | 2018 | 2885 | 0.150 |
Why?
| | Dasatinib | 1 | 2019 | 56 | 0.150 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 2018 | 22 | 0.150 |
Why?
| | Radiosurgery | 1 | 2022 | 392 | 0.150 |
Why?
| | Lymph Nodes | 2 | 2018 | 502 | 0.150 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 30 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2019 | 274 | 0.140 |
Why?
| | Varicellovirus | 1 | 2018 | 17 | 0.140 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 174 | 0.140 |
Why?
| | Monkey Diseases | 1 | 2018 | 25 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 388 | 0.130 |
Why?
| | Receptors, Complement | 1 | 2017 | 122 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 432 | 0.130 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2020 | 277 | 0.130 |
Why?
| | Transplantation Tolerance | 1 | 2017 | 37 | 0.130 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 353 | 0.130 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2017 | 65 | 0.130 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 400 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 208 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 415 | 0.120 |
Why?
| | Chemokines, CXC | 1 | 2016 | 71 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 482 | 0.120 |
Why?
| | Down-Regulation | 2 | 2016 | 641 | 0.120 |
Why?
| | Blood Substitutes | 1 | 1996 | 27 | 0.120 |
Why?
| | Crohn Disease | 1 | 2020 | 254 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2019 | 226 | 0.120 |
Why?
| | Mice, 129 Strain | 2 | 2013 | 86 | 0.120 |
Why?
| | Cytokines | 3 | 2020 | 2098 | 0.120 |
Why?
| | Immune Evasion | 1 | 2016 | 63 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 220 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 642 | 0.120 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.120 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 361 | 0.120 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 70 | 0.120 |
Why?
| | Papillomaviridae | 1 | 2016 | 133 | 0.120 |
Why?
| | Rhadinovirus | 1 | 2015 | 20 | 0.110 |
Why?
| | Aminopeptidases | 2 | 2024 | 22 | 0.110 |
Why?
| | V(D)J Recombination | 1 | 2014 | 8 | 0.110 |
Why?
| | Biomarkers | 3 | 2024 | 4174 | 0.110 |
Why?
| | Complement Activation | 1 | 2017 | 415 | 0.110 |
Why?
| | Adenosine | 2 | 2013 | 244 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 162 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 987 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2020 | 747 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2020 | 740 | 0.100 |
Why?
| | Gene Expression | 1 | 2019 | 1491 | 0.100 |
Why?
| | Mice, Inbred NOD | 1 | 2015 | 600 | 0.100 |
Why?
| | Combined Modality Therapy | 3 | 2023 | 1243 | 0.100 |
Why?
| | Perioperative Period | 1 | 2013 | 65 | 0.100 |
Why?
| | Hemoglobins | 1 | 1996 | 361 | 0.100 |
Why?
| | Virulence Factors | 1 | 2015 | 162 | 0.100 |
Why?
| | Graft Rejection | 1 | 2017 | 544 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 333 | 0.100 |
Why?
| | Lymphocytes, Null | 1 | 2012 | 3 | 0.100 |
Why?
| | Antigens | 2 | 2020 | 362 | 0.100 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2012 | 27 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2024 | 898 | 0.100 |
Why?
| | Thymus Gland | 1 | 2014 | 319 | 0.100 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 45 | 0.100 |
Why?
| | Thymoma | 1 | 2012 | 36 | 0.100 |
Why?
| | Computational Biology | 1 | 2018 | 661 | 0.100 |
Why?
| | Nerve Growth Factors | 1 | 2013 | 79 | 0.100 |
Why?
| | Aspirin | 1 | 1996 | 385 | 0.100 |
Why?
| | Pneumonia, Viral | 1 | 2018 | 374 | 0.100 |
Why?
| | Reperfusion | 1 | 2012 | 44 | 0.100 |
Why?
| | Jurkat Cells | 1 | 2012 | 138 | 0.090 |
Why?
| | Intraoperative Complications | 1 | 2013 | 148 | 0.090 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 2012 | 10 | 0.090 |
Why?
| | Lung | 3 | 2017 | 4134 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2020 | 882 | 0.090 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 20 | 0.090 |
Why?
| | Intestinal Diseases | 1 | 2012 | 42 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1819 | 0.090 |
Why?
| | Antigenic Variation | 1 | 2011 | 12 | 0.090 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 13 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2012 | 70 | 0.090 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1150 | 0.090 |
Why?
| | Cell Hypoxia | 1 | 2012 | 231 | 0.090 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2013 | 199 | 0.090 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 309 | 0.090 |
Why?
| | Hospital Mortality | 1 | 2016 | 924 | 0.090 |
Why?
| | Vaccines, Subunit | 1 | 2011 | 50 | 0.090 |
Why?
| | Perioperative Care | 1 | 2013 | 227 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 346 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 689 | 0.090 |
Why?
| | Nitric Oxide | 1 | 1996 | 900 | 0.090 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 97 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 325 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 469 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1764 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 892 | 0.080 |
Why?
| | Blotting, Western | 1 | 2013 | 1234 | 0.080 |
Why?
| | Cancer Vaccines | 1 | 2011 | 167 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1763 | 0.080 |
Why?
| | Purines | 1 | 2011 | 179 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 498 | 0.080 |
Why?
| | Sepsis | 1 | 2016 | 616 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 497 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1597 | 0.080 |
Why?
| | Colitis | 1 | 2012 | 266 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 299 | 0.080 |
Why?
| | Endothelium, Vascular | 1 | 1996 | 951 | 0.080 |
Why?
| | Female | 13 | 2020 | 75515 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2016 | 2003 | 0.080 |
Why?
| | Intestines | 1 | 2012 | 357 | 0.070 |
Why?
| | Integrin alpha4 | 1 | 2008 | 7 | 0.070 |
Why?
| | Male | 11 | 2020 | 69783 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2023 | 610 | 0.070 |
Why?
| | Interleukin-1 | 1 | 2012 | 968 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 691 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 859 | 0.070 |
Why?
| | Models, Immunological | 1 | 2008 | 101 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2021 | 1154 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2011 | 330 | 0.070 |
Why?
| | Gastric Mucosa | 1 | 2007 | 53 | 0.070 |
Why?
| | Gene Knockdown Techniques | 2 | 2018 | 330 | 0.060 |
Why?
| | Phenotype | 2 | 2021 | 3166 | 0.060 |
Why?
| | Virulence | 2 | 2015 | 268 | 0.060 |
Why?
| | Salmonella Infections | 1 | 2007 | 55 | 0.060 |
Why?
| | Salmonella enterica | 1 | 2007 | 57 | 0.060 |
Why?
| | Health | 1 | 2007 | 84 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 761 | 0.060 |
Why?
| | Immunity | 1 | 2007 | 140 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1056 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2363 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 858 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 58 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 165 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 34 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 57 | 0.050 |
Why?
| | Obesity | 1 | 2016 | 3004 | 0.050 |
Why?
| | Viral Plaque Assay | 1 | 2002 | 34 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 129 | 0.050 |
Why?
| | 3T3 Cells | 1 | 2002 | 164 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 109 | 0.050 |
Why?
| | Cell Communication | 2 | 2017 | 318 | 0.050 |
Why?
| | Kynurenine | 1 | 2023 | 118 | 0.050 |
Why?
| | Macrophages | 2 | 2019 | 1561 | 0.040 |
Why?
| | Smoking | 1 | 2009 | 1601 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2013 | 2797 | 0.040 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 27 | 0.040 |
Why?
| | Luciferases | 1 | 2021 | 150 | 0.040 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 41 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 911 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2020 | 1487 | 0.040 |
Why?
| | Cetuximab | 1 | 2021 | 105 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 234 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 7 | 0.040 |
Why?
| | Immunocompetence | 1 | 2000 | 44 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 89 | 0.040 |
Why?
| | Gene Targeting | 1 | 2000 | 83 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 72 | 0.040 |
Why?
| | Tumor Burden | 1 | 2021 | 312 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 419 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 37 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 88 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Neoplasms | 2 | 2024 | 2741 | 0.040 |
Why?
| | Mutation | 2 | 2023 | 4013 | 0.040 |
Why?
| | Interferons | 1 | 2021 | 195 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 25 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 328 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 824 | 0.040 |
Why?
| | Mice, SCID | 1 | 2000 | 367 | 0.040 |
Why?
| | Homeodomain Proteins | 2 | 2013 | 511 | 0.040 |
Why?
| | Transfection | 1 | 2021 | 943 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 129 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 355 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 151 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2019 | 171 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 134 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 737 | 0.040 |
Why?
| | DNA Repair | 1 | 2020 | 234 | 0.040 |
Why?
| | Gene Silencing | 1 | 2019 | 196 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 81 | 0.040 |
Why?
| | RNA Transport | 1 | 2017 | 26 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2021 | 425 | 0.030 |
Why?
| | Lymphocytes | 1 | 2020 | 398 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 36 | 0.030 |
Why?
| | Cell Cycle | 1 | 2020 | 597 | 0.030 |
Why?
| | Complement C3d | 1 | 2017 | 67 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 232 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 189 | 0.030 |
Why?
| | Radiotherapy | 1 | 2018 | 208 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 100 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 579 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1320 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 914 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2016 | 41 | 0.030 |
Why?
| | Arenaviridae Infections | 1 | 2016 | 17 | 0.030 |
Why?
| | Ovalbumin | 1 | 2017 | 196 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 203 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1319 | 0.030 |
Why?
| | Lectins, C-Type | 1 | 2016 | 63 | 0.030 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2016 | 11 | 0.030 |
Why?
| | Granzymes | 1 | 2016 | 50 | 0.030 |
Why?
| | Calcimycin | 1 | 1996 | 49 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 287 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 1996 | 49 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 419 | 0.030 |
Why?
| | Cyclic GMP | 1 | 1996 | 91 | 0.030 |
Why?
| | Renal Artery | 1 | 1996 | 40 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 204 | 0.030 |
Why?
| | B-Cell Activating Factor | 1 | 2015 | 21 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2020 | 7856 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 413 | 0.030 |
Why?
| | Neutralization Tests | 1 | 2015 | 81 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 228 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 74 | 0.030 |
Why?
| | Cell Survival | 1 | 2018 | 1129 | 0.030 |
Why?
| | Acetylcholine | 1 | 1996 | 203 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 852 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 1996 | 242 | 0.030 |
Why?
| | Cyclic AMP | 1 | 1996 | 219 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 58 | 0.030 |
Why?
| | Immunoblotting | 1 | 2015 | 310 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1737 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2014 | 24 | 0.030 |
Why?
| | Femoral Artery | 1 | 1996 | 184 | 0.030 |
Why?
| | Dogs | 1 | 1996 | 427 | 0.030 |
Why?
| | Autoimmunity | 1 | 2020 | 908 | 0.030 |
Why?
| | Interleukin-27 | 1 | 2014 | 15 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 28 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 63 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2014 | 40 | 0.030 |
Why?
| | California | 1 | 2016 | 462 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2014 | 63 | 0.030 |
Why?
| | DNA Primers | 1 | 2015 | 510 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2018 | 720 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2016 | 205 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1093 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 302 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 990 | 0.030 |
Why?
| | Netrin-1 | 1 | 2013 | 15 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 388 | 0.030 |
Why?
| | Imidazoles | 1 | 2014 | 244 | 0.020 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2012 | 26 | 0.020 |
Why?
| | Adenosine Deaminase | 1 | 2013 | 40 | 0.020 |
Why?
| | Adult | 3 | 2023 | 39177 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2016 | 287 | 0.020 |
Why?
| | Vasodilation | 1 | 1996 | 516 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 1996 | 854 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 223 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 8 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1251 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 29 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 30 | 0.020 |
Why?
| | Albuminuria | 1 | 2013 | 185 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2012 | 125 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 33 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4073 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 76 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 501 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 480 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 207 | 0.020 |
Why?
| | Apoptosis | 1 | 2020 | 2574 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2064 | 0.020 |
Why?
| | Antigens, CD | 1 | 2014 | 539 | 0.020 |
Why?
| | Receptors, Purinergic | 1 | 2011 | 19 | 0.020 |
Why?
| | DNA Methylation | 1 | 2016 | 645 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2793 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2011 | 184 | 0.020 |
Why?
| | Chemotaxis | 1 | 2011 | 133 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1448 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 1003 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1357 | 0.020 |
Why?
| | Alleles | 1 | 2012 | 891 | 0.020 |
Why?
| | Fibroblasts | 1 | 2015 | 1020 | 0.020 |
Why?
| | Inflammasomes | 1 | 2011 | 134 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 889 | 0.020 |
Why?
| | Immunoglobulin Class Switching | 1 | 2009 | 21 | 0.020 |
Why?
| | Phagocytosis | 1 | 2011 | 388 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3292 | 0.020 |
Why?
| | Aged | 2 | 2020 | 24574 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2011 | 519 | 0.020 |
Why?
| | Infection Control | 1 | 2009 | 167 | 0.020 |
Why?
| | Epitopes | 1 | 2009 | 477 | 0.020 |
Why?
| | Organ Specificity | 1 | 2007 | 312 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2013 | 1069 | 0.020 |
Why?
| | Middle Aged | 2 | 2020 | 34434 | 0.020 |
Why?
| | Critical Illness | 1 | 2012 | 837 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1478 | 0.010 |
Why?
| | Stroke | 1 | 2013 | 1154 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1703 | 0.010 |
Why?
| | Vaccines | 1 | 2009 | 406 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 16273 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 10438 | 0.010 |
Why?
| | Vaccination | 1 | 2009 | 1467 | 0.010 |
Why?
|
|
Clambey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|